Skip to main content
SpringerLink
Log in

Evidence for a role of decitabine in the treatment of myeloid sarcoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405

    Article  PubMed  Google Scholar 

  2. Solh M, Solomon S, Morris L, Holland K, Bashey A (2016) Extramedullary acute myelogenous leukemia. Blood Rev 30:333–339

    Article  PubMed  Google Scholar 

  3. Zebisch A, Cerroni L, Beham-Schmid C, Sill H (2003) Therapy-related leukemia cutis: case study of an aggressive disorder. Ann Hematol 82:705–707

    Article  CAS  PubMed  Google Scholar 

  4. Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, Estrov Z (2013) Is acute myeloid leukemia a liquid tumor? Int J Cancer 133:534–543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Slomowitz SJ, Shami PJ (2012) Management of extramedullary leukemia as a presentation of acute myeloid leukemia. J Natl Compr Canc Netw 10:1165–1169

    PubMed  Google Scholar 

  6. Bakst RL, Tallman MS, Douer D, Yahalom J (2011) How I treat extramedullary acute myeloid leukemia. Blood 118:3785–3793

    Article  CAS  PubMed  Google Scholar 

  7. Ganzel C, Manola J, Douer D, Rowe JM, Fernandez HF, Paietta EM, Litzow MR, Lee JW, Luger SM, Lazarus HM, Cripe LD, Tallman MS (2016) Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN Cancer Research Group Trials, 1980–2008. J Clin Oncol

  8. Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M, Gotze KS (2016) A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics 8:71. doi:10.1186/s13148-016-0237-y

    Article  PubMed  PubMed Central  Google Scholar 

  9. Singh SN, Cao Q, Gojo I, Rapoport AP, Akpek G (2012) Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT. Bone Marrow Transplant 47:1008–1009

    Article  CAS  PubMed  Google Scholar 

  10. Modi G, Madabhavi I, Panchal H, Patel A, Anand A, Parikh S, Jain P, Revannasiddaiah S, Sarkar M (2015) Primary vaginal myeloid sarcoma: a rare case report and review of the literature. Case Rep Obstet Gynecol 2015:957490. doi:10.1155/2015/957490

    PubMed  PubMed Central  Google Scholar 

Download references

Author contributions

MG, AW, HS, and AZ treated the patients and collected/reviewed clinical data. SS performed and analyzed FDG-PET/CT scans. MG and AZ drafted the manuscript. All authors read and approved the final typescript.

Author information

Authors and Affiliations

  1. Division of Hematology, Medical University of Graz, Graz, Austria

    Max Gornicec, Albert Wölfler, Heinz Sill & Armin Zebisch

  2. Department of Radiology, Division of Nuclear Medicine, Medical University of Graz, Graz, Austria

    Susanne Stanzel

Authors
  1. Max Gornicec
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Albert Wölfler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susanne Stanzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heinz Sill
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Armin Zebisch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Armin Zebisch.

Ethics declarations

Funding

No funding was received for this work.

Conflict of interest

Dr Wölfler received research funding and honoraria from Celgene and participated in advisory boards of Celgene and Janssen-Cilag. Dr Sill received research funding and honoraria from Celgene and participated in advisory boards of Celgene. Dr Zebisch received honoraria from Celgene. All other authors declare that they have no conflict of interest.

Ethical approval and informed consent

This study was approved by the institutional review board of the Medical University of Graz, Austria, and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gornicec, M., Wölfler, A., Stanzel, S. et al. Evidence for a role of decitabine in the treatment of myeloid sarcoma. Ann Hematol 96, 505–506 (2017). https://doi.org/10.1007/s00277-016-2870-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2870-0

Keywords

Search

Navigation